Phenytoin (Epanutin) Associated Hodgkin's Disease

Area of Science:

• Oncology
• Pharmacology
• Pathology

Background:

• Phenytoin (Epanutin) is an anticonvulsant medication with known potential side effects.
• Lymphoid malignancies encompass a range of cancers affecting the lymphatic system.
• Drug-induced cancers are a recognized, though rare, phenomenon.

Purpose of the Study:

• To report a case of Hodgkin's disease associated with long-term phenytoin use.
• To review other documented cases of phenytoin-associated lymphoid malignancy.
• To raise awareness of potential oncogenic risks associated with phenytoin.

Main Methods:

• Case report detailing a patient's diagnosis and treatment history.
• Literature review of English-language publications on phenytoin and lymphoid malignancy.
• Analysis of clinical presentation and pathological subtype.

Main Results:

• A patient developed Hodgkin's disease of the lymphocyte predominance subtype after two years of phenytoin treatment.
• Four additional cases of phenytoin-associated lymphoid malignancy were identified in the English literature.
• The findings suggest a potential association between phenytoin and specific types of lymphoid cancers.

Conclusions:

• Phenytoin therapy may be associated with an increased risk of developing Hodgkin's disease, particularly the lymphocyte predominance subtype.
• Further investigation is warranted to elucidate the mechanisms underlying this potential association.
• Clinicians should consider phenytoin as a possible factor in patients presenting with lymphoid malignancies.